Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus.
Article Type: Brief article
Subject: Type 2 diabetes (Care and treatment)
Cardiovascular diseases (Risk factors)
Authors: Mittermayer, F.
Pleiner, J.
Francesconi, M.
Wolzt, M.
Pub Date: 04/01/2010
Publication: Name: Alternative Medicine Review Publisher: Thorne Research Inc. Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2010 Thorne Research Inc. ISSN: 1089-5159
Issue: Date: April, 2010 Source Volume: 15 Source Issue: 1
Geographic: Geographic Scope: United States Geographic Code: 1USA United States
Accession Number: 225739707
Full Text: Elevated asymmetric dimethylarginine (ADMA) concentrations predict cardiovascular events in patients with type 2 diabetes mellitus (T2DM). It has been shown that alpha-lipoic acid (ALA) improves endothelial function and oxidative stress in these patients. The present study investigated if ALA reduces ADMA in patients with T2DM. Plasma concentrations of ADMA, L-arginine and symmetric dimethylarginine (SDMA) were determined in a double-blind, randomized, placebo-controlled study in patients with T2DM. Intravenous ALA (n = 16) or placebo (n = 14) was administered daily for 3 weeks. ALA reduced ADMA while no change was observed with placebo (mean change -0.05 micromol/l[95% CI: 0.01; -0.09] vs. 0.01 micromol/l [95% Ch -0.05; -0.03]; ANOVA p = 0.031). SDMA and L-arginine were not affected by ALA. In conclusion ALA treatment reduces ADMA in patients with T2DM. Long-term studies need to demonstrate if ALA may cause cardiovascular risk reduction.

Transl Res 2010;155:6-9.
Gale Copyright: Copyright 2010 Gale, Cengage Learning. All rights reserved.